After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out about its atopic dermatitis treatment Ebglyss. Ebglyss is a once-monthly injection that was approved to treat moderate-to-severe eczema in people who haven’t responded well to prescription topical therapies.

Eli Lilly wants the most optimal locations to host its new manufacturing facilities in the U.S.—and it’s open to pitche | Eli Lilly has established an online portal to accept submissions for possible locations of future U.

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn’t stopped the

Pharmaceutical giant Eli Lilly announced Wednesday that it plans to invest roughly $27 billion in United States manufacturing more than doubling its investment over the past five years. The company said this will be the largest pharmaceutical manufacturing investment in United States history.

Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its latest attempt to fend off competition from copies of its weight-loss drug.

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

With this latest announcement, Lilly has committed to investing more than $50 billion in U.S. manufacturing since 2020.

Eli Lilly ( LLY) announced Wednesday that it is ramping up US manufacturing, adding four new sites to help increase the production of key drug ingredients. Three of the four sites will produce active pharmaceutical ingredients (APIs), which are key ingredients in drugs.

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, the growing measles outbreak in Texas,

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a deal worth up to $50 million in biobucks. | Eli Lilly has acquired Organovo’s lead asset,